Evidence map›Paper›PMID 33116614›Full record

ArticleOncoTargets and therapy2020

Triple Discordances in Receptor Status During Breast Cancer Local Progression and Metastases: Case Report and Literature Review.

Adrian Martuszewski, Patrycja Paluszkiewicz, Mateusz Nowak, Krzysztof Szewczyk, Urszula Staszek-Szewczyk

Erratum issuedOpen access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Adrian MartuszewskiWroclaw Medical University, Wroclaw, Poland.ORCID 0000-0002-3620-6380
Patrycja PaluszkiewiczWroclaw Medical University, Wroclaw, Poland.ORCID 0000-0002-5701-9349
Mateusz NowakWroclaw Medical University, Wroclaw, Poland.ORCID 0000-0002-7673-3804
Krzysztof SzewczykWroclaw Medical University, Department of Oncology, Division of Surgical Oncology, Wroclaw, Poland.ORCID 0000-0002-0575-5707
Urszula Staszek-SzewczykWroclaw Medical University, Department of Oncology, Division of Surgical Oncology, Wroclaw, Poland.ORCID 0000-0002-5122-1685
Wroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most common female malignant neoplasm in Poland and around the world. Precise determination of tumor molecular profile allows application of appropriate anticancer therapy, increasing the chances of recovery. A 28-year-old woman detected a thickening in her left breast. Mammography showed a change measuring 60 mm (radiologically BIRADS 5). The biopsy revealed invasive ductal carcinoma, luminal subtype B, HER2 positive (cT3N1M0). Neoadjuvant chemotherapy was administered and then breast conserving surgery was performed. In postoperative histopathology cancer, biological subtype was evaluated: HER2 positive, nonluminal (ypT2ypN0cM0). Then, postoperative radiotherapy was performed. After 14 months, breast ultrasonography (US) and mammography (MGF) revealed the presence of suspicious changes (BIRADS 4). Tru-cut biopsy confirmed cancer recurrence (luminal subtype B, HER2 negative, ER negative, PgR: 10%, Ki-67: 70%). Despite implemented and modified chemotherapy regimens, local progression occurred. Genetic testing excluded

Indexed as

biological subtypepersonalized treatmentphase disease

Identifiers

PMID33116614
PMCPMC7569034
OpenAlexW3092530358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.